N-terminal Sequencing: Unlocking Protein Identity with HRMS

Reliable Edman degradation sequencing and mass spectrometry-based solutions for protein identification, peptide sequencing, and biopharmaceutical quality control. Confirm your protein’s identity and integrity with unambiguous, regulatory-ready data.

10+ years in protein sequencing services
Expertise in Edman degradation sequencing & MS analysis
Regulatory-compliant reporting for FDA/EMA submissions
Trusted by 500+ global biotech & pharma clients

Request a Quote

Comprehensive N-terminal Sequencing Services

In biopharmaceutical development, the “beginning” of your protein tells a critical story. Is the sequence correct? Has the starting methionine been cleaved? Are there unexpected modifications? N-terminal sequencing provides the definitive answers to these questions, serving as a fundamental check for protein identity, purity, and structural fidelity.

Think of it as verifying the first lines of a crucial document. Any error at the start can have cascading consequences. Our N-terminal sequencing services use proven methodologies to give you unambiguous characterization of your protein’s N-terminus, a non-negotiable step for quality control and regulatory compliance.

We offer a dual-platform approach, combining the classical gold-standard method with modern technology to ensure no critical detail is missed.

Our Core Methodologies N-terminal SequencingServices

Edman Degradation Sequencing: The Gold Standard

For decades, Edman degradation sequencing has been the benchmark for direct, step-wise N-terminal analysis. It’s a robust, chemical process that reliably sequences the first 10-50 amino acids from the N-terminus of proteins and peptides.

Ideal For: Pure, soluble proteins and peptides with a free (unblocked) N-terminus.
Key Advantage: Provides direct, unambiguous sequence data without the need for a database, making it perfect for confirming the identity of recombinant proteins and synthetic peptides.
Application: Routine QC, batch-to-batch consistency checks, and confirming the N-terminal sequence of monoclonal antibodies and biosimilars.

Mass Spectrometry-Based Sequencing: Power for Complexity

When proteins have modified or “blocked” N-termini (e.g., by acetylation or pyroglutamate formation), or when sample amounts are very low, mass spectrometry (MS) becomes the tool of choice.

Ideal For: Proteins with blocked N-termini, complex mixtures, and in-depth characterization requiring high sensitivity.
Key Advantage: Can identify post-translational modifications (PTMs) and analyze samples that are incompatible with Edman chemistry. It complements Edman by solving more challenging puzzles.
Application: Characterizing novel proteins, investigating processing errors, and detailed biopharmaceutical protein characterization.

Peptide Sequencing Services

Beyond full proteins, we provide dedicated peptide sequencing services for synthetic peptides, peptide maps, and fragments. This is essential for vaccine development, peptide-based therapeutics, and confirming the structure of critical epitopes.

Ideal For: Synthetic peptide QC, mapping proteolytic digests, and characterizing peptide impurities.
Key Advantage: We select the optimal method (Edman or MS) based on your peptide’s properties and the required information, ensuring accuracy and efficiency.

Why Partner With Us? Expertise You Can Build Upon

Choosing a partner for N-terminal sequencing means trusting them with a fundamental aspect of your product’s identity. Here’s why leading companies rely on us:

Regulatory-Compliant Characterization: Our processes and documentation are designed to meet the stringent requirements of global health authorities. We provide the detailed, audit-ready reports you need for successful FDA/EMA submissions as part of your biopharmaceutical protein characterization package.
Dual-Method Expertise: We don’t rely on a single technology. Our experts will recommend the best approach—Edman degradation sequencing, mass spectrometry, or a combination of both—to solve your specific challenge, ensuring you get the right answer the first time.
Unmatched Technical Support: From project design to data interpretation, our scientists work as an extension of your team. We help you understand what the data means for your program, providing insights that go beyond a simple report.
Broad Therapeutic Experience: We have extensive experience across a wide range of molecules, including monoclonal antibodies, biosimilars, recombinant proteins, and novel biologics, giving us the context to understand your unique needs.
A Truly Global Partner: With a client base that includes top-tier CROs, CDMOs, pharmaceutical giants, and innovative biotech startups, we understand the pressures and timelines of drug development at every scale.

Characterization

Contact us

Error: Contact form not found.

Who We Serve: Supporting Innovation from Bench to Market

Our services are critical for any organization where protein integrity is paramount:

Biopharmaceutical Companies requiring identity confirmation for lead candidates and marketed products.
Biotechnology Startups needing definitive protein characterization to secure funding and advance pipelines.
CROs and CDMOs looking for a reliable, high-quality partner to support their clients’ analytical needs.
Academic Research Institutions conducting fundamental research on protein structure and function.
Clinical Research Labs developing protein-based diagnostics and therapeutics.

Request a Quote

Applications of N-terminal Protein Sequencing

N-terminal sequencing is a versatile tool with critical applications across the development lifecycle:

Protein Identification Services

Confirming that you have expressed the correct protein is the first step in any development program. Our protein identification services provide definitive proof of identity by reading the N-terminal sequence, ensuring your clone and expression system are working as intended.

Biopharmaceutical Protein Characterization

For regulatory submissions, you must demonstrate that your therapeutic protein’s structure is correct and consistent. N-terminal sequencing is a required test for biopharmaceutical protein characterization, providing essential data for IND, BLA, and biosimilar applications.

Peptide Sequencing Services

Whether you’re producing synthetic peptides for therapeutics or research, verifying the sequence is critical for quality control. Our peptide sequencing services ensure your peptides are synthesized correctly, identifying any deletion sequences or impurities.

Detection of Truncations and Modifications

Unexpected cleavage or N-terminal modifications can impact a protein’s stability and activity. N-terminal protein sequencing can detect these variations, such as incomplete signal peptide removal or the presence of pyroglutamate, helping you optimize production processes.

Quality Control for Biosimilars

For a biosimilar to be approved, its primary structure must match the originator. N-terminal sequencing provides direct, head-to-head comparison data, a crucial element in demonstrating analytical similarity.

Edman Degradation vs. Mass Spectrometry: Choosing the Right Tool

Analytical Aspect	Edman Degradation Sequencing	Mass Spectrometry Sequencing
Principle	Step-wise chemical cleavage of N-terminal amino acids.	Measurement of mass-to-charge ratio of ions; sequencing via fragmentation.
Sequence Information	Direct, de novo sequencing of the first 10-50 residues.	Indirect; requires interpretation of fragmentation patterns or database matching.
Best For	Pure proteins/peptides with a free N-terminus; routine QC, definitive identity confirmation.	Blocked N-termini, complex mixtures, low-abundance samples; identification of PTMs.
Key Limitation	Cannot sequence proteins with blocked N-termini (e.g., acetylated).	Requires sophisticated instrumentation and expertise; can be ambiguous without pure samples.
Role in Biopharma	Gold-standard for direct N-terminal sequence confirmation in QC and release testing.	Powerful for in-depth characterization, troubleshooting, and analyzing modified proteins.

Case Study: Verifying a Biosimilar mAb for FDA Submission

The Challenge: A biosimilar developer needed to conclusively demonstrate that the N-terminal sequence of their monoclonal antibody heavy and light chains were identical to the innovator product. This was a critical requirement for their FDA submission package.

Our Solution: We performed Edman degradation sequencing on purified samples of the antibody chains. The method provided clear, step-by-step sequence data for the first 15 cycles, offering direct and unambiguous proof of identity without reliance on comparative data.

The Outcome: The crisp, definitive chromatograms and sequence alignment report we provided became a key part of the analytical similarity section. The data clearly demonstrated identical N-terminal sequences, satisfying a major regulatory requirement and helping to streamline the agency’s review process.

FAQ About N-terminal Sequencing

Q1.What is N-terminal sequencing used for?

N-terminal sequencing is primarily used to determine the amino acid sequence at the beginning (N-terminus) of a protein or peptide. Its main applications include confirming the identity of a recombinant protein, checking for correct processing (e.g., signal peptide removal), detecting sequence variants or truncations, and as a critical quality control test for therapeutic proteins and biosimilars.

Q2.How does Edman degradation sequencing work?

In simple terms, Edman degradation sequencing is a cyclic chemical reaction. In each cycle, it selectively labels and removes the very first amino acid from the protein chain, which is then identified by chromatography. The process is repeated for the next amino acid, allowing us to “read” the sequence step-by-step from the N-terminus inward.

Q3.When should I use peptide sequencing services vs. full protein sequencing?

Peptide sequencing services are ideal for analyzing shorter chains (synthetic peptides) or specific fragments of a protein (e.g., from a digest). “Full protein sequencing” typically refers to determining the entire amino acid sequence, which is a much larger project usually achieved by sequencing overlapping peptides or using DNA sequencing. For most biopharmaceutical QC needs, N-terminal sequencing of the intact protein or its subunits is the standard requirement.

Q4.Can N-terminal sequencing detect protein modifications?

Yes, to an extent. Edman degradation will fail if the N-terminus is chemically “blocked” (e.g., acetylated), which is itself a valuable piece of information. Mass spectrometry-based sequencing is excellent at identifying specific modifications like pyroglutamate formation or acetylation, as it can detect the mass change associated with the modification.

Q5.Are N-terminal sequencing results accepted by regulatory agencies?

Absolutely. N-terminal sequencing is a well-established and expected part of the analytical characterization package for biologic therapeutics. Data generated using validated Edman degradation sequencing or mass spectrometry methods are routinely submitted to and accepted by the FDA, EMA, and other global regulatory bodies.

Characterization

Contact us

Error: Contact form not found.